Skip to main content
. 2022 Feb 11;9:758464. doi: 10.3389/fmed.2022.758464

Table 4.

Panel-wide concordance of actionable mutations in 24 NSCLC cases that underwent both the tissue and plasma NGS testing.

Tissue NGS
Positive Negative Total
Plasma NGS Positive 9 2 11 PPA: 75.0% (95% CI: 42.8 to 94.5%)
NPA: 83.3% (95% CI: 51.6 to 97.9%)
OPA: 79.2% (95% CI: 57.9 to 92.9%)
Negative 3 10 13

PPA, positive percent agreement; NPA, negative percent agreement; OPA, overall percent agreement.